TC
TLOG

TFS Capital’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

TFS Capital’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-19,147
Closed -$113K – 1370
2014
Q2 		$113K Sell
19,147
-4,613
-19% -$26.2K 0.01% 1037
2014
Q1 		$152K Buy
+23,760
New +$214K 0.01% 1241

Other funds holding TLOG

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

TFS Capital's TLOG Position: Q3 2014 in Review

TFS Capital sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q3 2014, closing a stake of 19,147 shares — an estimated $113K sold.

TFS Capital first reported a position in TLOG in Q1 2014 and held it in 2 quarters. The position peaked at $152K in Q1 2014. 25 funds tracked by Wall St. Rank hold TLOG as of Q3 2014.

  • TFS Capital reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q3 2014 after selling out during the quarter.
  • TFS Capital sold 19,147 TetraLogic Pharmaceuticals Corporation shares in Q3 2014, an estimated $113K.
  • TFS Capital first reported a position in TetraLogic Pharmaceuticals Corporation in Q1 2014 and held it in 2 quarters.
  • TFS Capital's TetraLogic Pharmaceuticals Corporation position peaked at $152K in Q1 2014.
  • 25 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q3 2014.

Based on TFS Capital's 13F filing for Q3 2014, filed 6 Nov 2014.